Challenges with biomarkers in cancer drug discovery and development

Click to increase image sizeClick to decrease image size

Declaration of Interest

F Meric-Bernstam has received research funding from Novartis, AstraZeneca, Taiho, Genentech, Calithera, Debiopharma, Bayer Healthcare, PUMA, Aileron, Jounce, CytoMx, eFFECTOR Therapeutics, Zymeworks, Curis and Pfizer Inc. F Meric-Bernstam acted as a paid consultant for Dialecta and Sumitomo Dainippon Pharma as well an advisory committee/board member for Inflection Biosciences, Clearlight Diagnostics, Pieris, Darwin Health and GRAIL. TA Yap has received research funding from AstraZeneca, Vertex Pharmaceuticals and Clearbridge Biomedics. He is also an advisory board member for AstraZeneca, Pfizer Inc, EMD Serono, Clovis, Bristol-Myers Squibb, Ignyta, Roche, Janssen Pharmaceuticals, Atrin and Aduro and has received travel support from AstraZeneca, Bristol-Myers Squibb, Merck Sharp Dohme, Vertex Pharmaceuticals, GlaxoSmithKline, EMD Serono and Tesaro. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This work was supported by the Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, Cancer Prevention Research Institute of Texas (CPRIT) Precision Oncology Decision Support Core grant RP150535, and the MD Anderson Cancer Center Support grant (P30 CA016672).